Search Medical Condition
Please enter condition
Please choose location

Porta Westfalica, Germany Clinical Trials

A listing of Porta Westfalica, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (104) clinical trials

PANORAMA - Real World Molecular Testing Treatment Patterns and Clinical Outcomes EGFR Mutation-Positive NSCLC

The objectives of this study are to assess molecular testing, treatment patterns, and associated outcomes among patients with EGFR (Epidermal Growth Factor Receptor) mutation-positive locally advanced or advanced NSCLC (Non-Small Cell Lung Cancer) who have progressed on or after EGFR-TKI (EGFR-Tyrosine Kinase Inhibitor) therapy post availability of a third-generation TKI ...

Phase N/A

0.0 miles

Learn More »

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

This is a prospective, open-label, multi-center, single arm, non-comparative phase II study in women with HR+/HER2- advanced breast cancer receiving palbociclib in addition to an aromatase inhibitor or fulvestrant. The study will take place in Germany (85 study centers). In total, 360 patients will be enrolled in this study. 6 ...

Phase

0.0 miles

Learn More »

Documentation of Humira in Psoriasis Patients in Routine Clinical Practice

Postmarketing Observational Study to Evaluate the Work Productivity, Safety and Efficacy of Humira for the Treatment of Moderate to Severe Plaque Psoriasis in Daily Clinical Practice. The primary objectives of the PMOS are to explore changes in health related care utilization data by the evaluation of: the number of missed ...

Phase N/A

0.0 miles

Learn More »

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA

The multi-center, prospective PRODAST study is investigating patients with non-valvular atrial fibrillation (AF) who experienced an ischemic stroke or a transient ischemic attack (TIA) recently ( 1 week) both with and without previous oral anticoagulation. It consists of a baseline visit and a 3 months central follow-up for patients who ...

Phase N/A

4.5 miles

Learn More »

Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer

OBJECTIVES: Primary - Compare the disease-free survival rate in women with stage III breast cancer treated with adjuvant chemotherapy with vs without darbepoetin alfa. Secondary - Compare local recurrence and overall survival in patients receiving these regimens. - Compare toxicity of these regimens in these patients. - Compare quality of ...

Phase N/A

4.78 miles

Learn More »

Observation Combination Chemotherapy Radiation Therapy and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

OBJECTIVES: Primary - Determine the event-free survival (EFS) of younger patients with newly diagnosed neuroblastoma categorized in the low-risk group (LRG) who undergo observation only or receive combination chemotherapy. - Compare the EFS rate in patients with neuroblastoma categorized in the medium-risk group (MRG) treated with combination induction therapy, maintenance ...

Phase

4.78 miles

Learn More »

A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely active CD.

Phase

4.78 miles

Learn More »

Vedolizumab Study With Inflammatory Bowel Disease Patients in Germany

The IBD-patients will be prospectively documented in the BIOibd-Registry. The diagnosis is made in accordance with current DGVS/ECCO UC/CD guidelines. There are the following inclusion and exclusion criteria: Inclusion Criteria: IBD-patients (UC/CD) aged 18-80 years at enrollment Written informed consent is given Exclusion Criteria:Lack of adequate documentation possibilities Malignant disease ...

Phase N/A

4.78 miles

Learn More »

Post-Marketing Use Of Inflectra (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease

The study will be conducted according to good clinical practice (GCP) guidelines and data source will be validated. The source data will consist of the hospital medical records and monitoring will be organized on a regular basis. Data for the study will be entered into an web based electronic data ...

Phase N/A

4.78 miles

Learn More »

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

This two-part, part 1: open-label extension (OLE) and part 2: safety monitoring (SM) study will examine the efficacy and safety of continued etrolizumab treatment in moderate to severe ulcerative colitis (UC) participants previously enrolled in etrolizumab Phase II/III studies. Participants with moderate to severe UC who were enrolled in the ...

Phase

4.78 miles

Learn More »